Monte Rosa Therapeutics, Inc. — Revenue by Fiscal Year
3 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/dcd58359-afe2-4d82-b7d1-26a3269334b6/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $123.7M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-109360 |
| FY 2024 | $75.6M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-042344 |
| FY 2023 | $0 | 2023-01-01 – 2023-12-31 | evidence 0000950170-25-042344 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Monte Rosa Therapeutics, Inc. — all facts · Net Income · Operating Income